PET/CT Imaging in Carriers of TTR Mutations

A. Pathogenic TTR Allele Carriers without HF Inclusion: * men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician) * have already completed the protocol for NCT05489549 at UT Southwestern only Exclusion: * a self-reported history or clinical history of HF * other known causes of cardiomyopathy * history of light-chain cardiac amyloidosis * prior type 1 myocardial infarction * cardiac transplantation * liver transplantation * body weight or habitus that exceeds the site-specific PET/CT parameters * estimated glomerular filtration rate ≤30 mL/min/1.73 m2 * inability to safely undergo PET/CT * participating in a clinical trial for ATTR treatments or taking a fibril deleting agent * pregnancy or breastfeeding * patients taking heparin or heparin derivatives for anticoagulation * allergy to potassium iodide * known uncorrected thyroid disorder B. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment): Inclusion: * men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician) * hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein * TTR gene sequencing confirming the TTR variant * have already completed the protocol for NCT05489549 at UT Southwestern only Exclusion: * other known causes of cardiomyopathy * history of light-chain cardiac amyloidosis * cardiac transplantation * liver transplantation * history of type I myocardial infarction * body weight or habitus that exceeds the site-specific PET/CT parameters * estimated glomerular filtration rate ≤30 mL/min/1.73 m2 * inability to safely undergo PET/CT * participating in a clinical trial for ATTR treatments or taking a fibril deleting agent * patients taking heparin or heparin derivatives for anticoagulation * pregnancy or breastfeeding * allergy to potassium iodide * known uncorrected thyroid disorder C. Non-carrier race-matched controls: Inclusion: * men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician * have previously enrolled in the Dallas Heart Study Exclusion: * a self-reported history or clinical history of HF * other known causes of cardiomyopathy * history of light-chain cardiac amyloidosis * prior type 1 myocardial infarction * cardiac transplantation * liver transplantation * body weight or habitus that exceeds the site-specific PET/CT parameters * estimated glomerular filtration rate ≤30 mL/min/1.73 m2 * inability to safely undergo PET/CT * participating in a clinical trial for ATTR treatments or taking a fibril deleting agent * patients taking heparin or heparin derivatives for anticoagulation * pregnancy or breastfeeding * allergy to potassium iodide * known uncorrected thyroid disorder